- Home
- YQ vs CLRB Comparison
YQ vs CLRB Comparison
Compare YQ & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- CLRB
- Stock Information
- Founded
- YQ 2012
- CLRB 2002
- Country
- YQ China
- CLRB United States
- Employees
- YQ N/A
- CLRB N/A
- Industry
- YQ Other Consumer Services
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- CLRB Health Care
- Exchange
- YQ Nasdaq
- CLRB Nasdaq
- Market Cap
- YQ 11.7M
- CLRB 12.6M
- IPO Year
- YQ 2020
- CLRB N/A
- Fundamental
- Price
- YQ $1.79
- CLRB $0.31
- Analyst Decision
- YQ
- CLRB Hold
- Analyst Count
- YQ 0
- CLRB 1
- Target Price
- YQ N/A
- CLRB N/A
- AVG Volume (30 Days)
- YQ 51.2K
- CLRB 619.5K
- Earning Date
- YQ 06-04-2025
- CLRB 05-13-2025
- Dividend Yield
- YQ N/A
- CLRB N/A
- EPS Growth
- YQ N/A
- CLRB N/A
- EPS
- YQ N/A
- CLRB N/A
- Revenue
- YQ $25,922,648.00
- CLRB N/A
- Revenue This Year
- YQ N/A
- CLRB N/A
- Revenue Next Year
- YQ N/A
- CLRB N/A
- P/E Ratio
- YQ N/A
- CLRB N/A
- Revenue Growth
- YQ 10.68
- CLRB N/A
- 52 Week Low
- YQ $1.26
- CLRB $0.22
- 52 Week High
- YQ $3.19
- CLRB $3.51
- Technical
- Relative Strength Index (RSI)
- YQ 52.34
- CLRB 53.10
- Support Level
- YQ $1.51
- CLRB $0.23
- Resistance Level
- YQ $1.98
- CLRB $0.32
- Average True Range (ATR)
- YQ 0.26
- CLRB 0.03
- MACD
- YQ 0.03
- CLRB 0.00
- Stochastic Oscillator
- YQ 51.35
- CLRB 90.33
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers to assist students, teachers, schoolmasters, and educational authorities across China to achieve data-driven teaching, learning, and assessment. Geographically group operates in China.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.